Latest UCLA's Jonsson Comprehensive Cancer Center Stories
Researchers have identified a prognostic marker in the most common form of chronic leukemia that can help to distinguish which patients should start treatment quickly from those who can safely delay treatment, perhaps for years.
Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it.
Researchers from UCLA's Jonsson Comprehensive Cancer Center, together with scientists from 12 other sites in the United States and Australia, report for the first time that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated.
Breast cancer stem cells are thought to be the sole source of tumor recurrence and are known to be resistant to radiation therapy and don't respond well to chemotherapy.
Quality of life in younger patients treated for breast cancer is seriously compromised and these women suffer from severe psychological distress, infertility, premature menopause, a decrease in physical activity and weight gain.
As cancer researchers continue to identify genetic mutations driving different cancer subtypes, they are also creating a catalog of possible targets for new treatments.